Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Novo Nordisk’s study shows reductions in blood sugar and weight compared with dulaglutide for type 2 diabetes, sales in diabetes, obesity increased
February 1, 2018 Off

Novo Nordisk’s study shows reductions in blood sugar and weight compared with dulaglutide for type 2 diabetes, sales in diabetes, obesity increased

By Dino Mustafić

Novo Nordisk has published the results for semaglutide from a study aiming to test the treatment for type 2 diabetes.

STADA announces the new CEO, to step in in September
February 1, 2018 Off

STADA announces the new CEO, to step in in September

By Dino Mustafić

Stada has announced the new name to succeed the current CEO Claudio Albrecht in September this year.

Vertex takes next step in testing medicine to treat the underlying cause of  cystic fibrosis
February 1, 2018 Off

Vertex takes next step in testing medicine to treat the underlying cause of cystic fibrosis

By Dino Mustafić

Vertex Pharmaceuticals will move its cystic fibrosis treatment VX-659 and VX-445 into Phase 3, the company said Wednesday, after the initial…

February 1, 2018 Off

Nordic Nanovector names new leader for communication with investors and media

By Dino Mustafić

Nordic Nanovector ASA has appointed Malene Brondberg as Vice President, Investor Relations and Corporate Communications. Malene will lead the engagement and…

Zogenix sends last patient into second Phase 3 trial for its supporting treatment for Dravet syndrome young patients
January 31, 2018 Off

Zogenix sends last patient into second Phase 3 trial for its supporting treatment for Dravet syndrome young patients

By Dino Mustafić

Zogenix, a NASDAQ-listed pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, has randomized the last…

Alkermes waits FDA’s green light for its investigational depressive disorder treatment
January 31, 2018 Off

Alkermes waits FDA’s green light for its investigational depressive disorder treatment

By Dino Mustafić

Alkermes will attempt to get new approval from the USFDA for its investigational drug for treating major depressive disorder (MDD).

Gemphire Therapeutics seeks evidence for gemcabene as treatment for pediatric nonalcoholic fatty liver disease
January 31, 2018 Off

Gemphire Therapeutics seeks evidence for gemcabene as treatment for pediatric nonalcoholic fatty liver disease

By Dino Mustafić

Gemphire Therapeutics, a US based clinical-stage biopharmaceutical company focused on therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), has…

Filament, University of Ottawa, CHEO partner up in $7.4M project funded by Genome Canada and CIHR to study inflammatory bowel disease treatment
January 31, 2018 Off

Filament, University of Ottawa, CHEO partner up in $7.4M project funded by Genome Canada and CIHR to study inflammatory bowel disease treatment

By Dino Mustafić

Filament BioSolutions, a New York-based clinical nutrition therapeutics specialist from announced a collaboration with the University of Ottawa and Children’s…

AIT Therapeutics acquires license to eNOGenerator from NitricGen for $2M plus milestones
January 31, 2018 Off

AIT Therapeutics acquires license to eNOGenerator from NitricGen for $2M plus milestones

By Dino Mustafić

AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients…

January 31, 2018 Off

Sanofi asks EMA to review drug for sleeping sickness

By Dino Mustafić

Sanofi has asked the European Medicines Agency (EMA) to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being…

Posts pagination

Previous 1 … 5,692 5,693 5,694 … 5,889 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

June 17, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine